This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Palau Pharma, S.A.
Drug Names(s): UR-13870
Description: UR-13870 is an orally active, low molecular weight p38 MAP kinase inhibitor.
Activation of the p38 MAPK pathway plays a crucial role inthe production of pro-inflammatory cytokines, including IL-1, TNF alpha, and IL-6. Because ofits broad pro-inflammatory role in several in vitro systems, the inhibition of the p38pathway has been advocated as a novel target to treat inflammatory diseases.
Additional information available to subscribers only: